Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies-Louvain-La-Neuve – page 56

1 888 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies-Louvain-La-Neuve at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies-Louvain-La-Neuve

Open in trial search

Study on Minocycline and Celecoxib for Patients with Major Depressive Disorder Not Responding to Antidepressants

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Celecoxib
  • Sponsor:University Of Antwerp

Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Universitair Medisch Centrum Groningen

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Cystic fibrosis

Recruiting

Study on Long-Term Safety and Effectiveness of Vanzacaftor, Tezacaftor, and Deutivacaftor for Cystic Fibrosis in Patients Aged 1 Year and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of Microdystrophin (GNT0004) Gene Therapy for Duchenne Muscular Dystrophy in Boys Who Can Walk

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Genethon

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm

Recruiting

Study on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alizapride
  • Sponsor:Institut Jules Bordet

Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Takeda Development Center Americas Inc.

Study on Atypical Teratoid/Rhabdoid Tumors in Children Using Dactinomycin, Carboplatin, and Cyclophosphamide

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Study on the Safety and Effect of EXOB-001 in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Sodium Chloride
  • Sponsor:Exo Biologics

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

What the registry says about research in the country

01 Hematology & Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.

  • Blood Cancer Therapeutics
  • Novel Drug Combinations
  • Treatment Resistance

This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.